Yoshiaki Yamamoto

Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial

Thomas Powles, Tibor Csőszi, Mustafa Özgüroğlu et al. · The Lancet Oncology · 2021 · 627 citations · Full text

First-line Therapy, Urology, Chemotherapy Versus Chemotherapy +7

Pembrolizumab versus placebo as post-nephrectomy adjuvant therapy for clear cell renal cell carcinoma (KEYNOTE-564): 30-month follow-up analysis of a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial

Thomas Powles, Piotr Tomczak, Se Hoon Park et al. · The Lancet Oncology · 2022 · 262 citations · Full text

Generation 2.5 Antisense Oligonucleotides Targeting the Androgen Receptor and Its Splice Variants Suppress Enzalutamide-Resistant Prostate Cancer Cell Growth

Yoshiaki Yamamoto, Yohann Loriot, Eliana Beraldi et al. · Clinical Cancer Research · 2015 · 122 citations

Overexpression of BUBR1 is associated with chromosomal instability in bladder cancer

Yoshiaki Yamamoto, Hideyasu Matsuyama, Yasuyo Chochi et al. · Cancer Genetics and Cytogenetics · 2007 · 107 citations

Urology, Oncology, Genitourinary Cancer +8

Levels and regional trends of persistent organochlorines and polybrominated diphenyl ethers in Asian breast milk demonstrate POPs signatures unique to individual countries

Koichi Haraguchi, Akio Koizumi, Kayoko Inoue et al. · Environment International · 2009 · 106 citations · Full text

Environmental Chemistry, Global Health, Environmental Health +12